Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
TTTav66 Member Profile
 
Followed By 19
Posts 348
Boards Moderated 0
Alias Born 12/10/15
160x600 placeholder
Anavex Life Sciences EPS beats by $0.03 Seeking Alpha - 5/13/2021 7:11:29 AM
Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook GlobeNewswire Inc. - 5/13/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit GlobeNewswire Inc. - 5/7/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 GlobeNewswire Inc. - 5/6/2021 7:00:00 AM
Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development GlobeNewswire Inc. - 5/5/2021 7:00:00 AM
Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference GlobeNewswire Inc. - 4/26/2021 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/12/2021 4:06:51 PM
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials o... GlobeNewswire Inc. - 4/12/2021 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/9/2021 5:07:26 PM
Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire Inc. - 4/8/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021 GlobeNewswire Inc. - 4/7/2021 7:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/1/2021 4:14:18 PM
DSMB recommends continuation of Anavex Life's late-stage Alzheimer’s study Seeking Alpha - 3/31/2021 7:14:03 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of... GlobeNewswire Inc. - 3/31/2021 7:00:00 AM
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical T... GlobeNewswire Inc. - 3/16/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease ... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit GlobeNewswire Inc. - 2/19/2021 7:00:00 AM
Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 GlobeNewswire Inc. - 2/18/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:07:35 PM
Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. InvestorsHub NewsWire - 2/12/2021 6:26:34 AM
Anavex Life Sciences EPS in-line Seeking Alpha - 2/11/2021 7:22:45 AM
Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook GlobeNewswire Inc. - 2/11/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2... GlobeNewswire Inc. - 2/8/2021 7:00:00 AM
TTTav66   Monday, 02/22/21 05:21:10 PM
Re: None
Post # of 310471 
Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease

Study Rationale:
We are testing ANAVEX2-73 (also known as blarcamesine), which previous research has shown helps improve behaviors as well as normalizes biochemical changes in a Parkinson’s disease animal model (6OHDA, which was supported by MJFF). In 132 patients with Parkinson’s disease dementia, the drug significantly improved cognitive function and memory as well as REM sleep. This includes complex cognitive tasks that impact quality of life such as making a choice between similar objects and remembering daily personal experiences, which could be impaired in Parkinson’s disease. In patients with Alzheimer’s disease a Phase 2a trial demonstrated a concentration dependent response in both cognition (MMSE) and function (ADCS-ADL) over 148 weeks (longer than 3 years).

The drug works by activating the Sigma-1 receptor protein in the brain. This protein helps brain cells stay healthy by reducing the effects of certain kinds of stress, preventing toxic proteins from building up in brain cells, and possibly protecting brain cells in other ways. This study is an important step in discovering if activating this protein will slow or reverse damage to brain cells and help them work normally again, thereby slowing or stopping Parkinson's progression.

Hypothesis:
We want to know if this new drug, ANAVEX2-73 (blarcamesine) can safely travel through the body to the final destination in parts of the brain most affected by Parkinson’s disease, which will help us determine if this new drug can help people with Parkinson’s disease.

Study Design:
In this study, researchers will give ANAVEX2-73 (blarcamesine) to up to 24 patients with Parkinson’s disease and healthy volunteers. The drug will be bound to a special tag or marker which will allow us to visualize the drug as it moves through the body to brain, using a medical imaging tool called Positron Emission Tomography (PET).

The researchers will also take blood samples from patients to learn about how the drug breaks down in the body to make sure it is safe and has minimal side effects.

Impact on Diagnosis/Treatment of Parkinson’s Disease:
This project will help us understand if this drug can safely make its way to the brain cells that are affected by Parkinson’s disease. This study may lead to a new treatment for Parkinson’s disease that will reduce or even reverse symptoms with improvements in the ability to walk, talk, eat, and smile, especially when combined with other medications.

Next Steps for Development:
If this study is successful, the drug will be tested in more patients and at different doses. This “efficacy testing” would determine the best dose of the drug to help people with Parkinson’s disease and whether it performs better than existing medications for Parkinson’s disease (or if a combination treatment is better).

https://www.michaeljfox.org/grant/evaluation-anavex2-73-blarcamesine-participants-parkinsons-disease

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences